Mystic Pharmaceuticals has got a non-taxable grant of $245,000 related to its VersiDoser delivery platform under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.

The VersiDoser delivery platform is said to be a liquid delivery platform that comprises novel unit dose blister packaging, proprietary intranasal and ophthalmic delivery devices and aseptic manufacturing production technologies.

The VersiDoser delivery platform utilises a proprietary manufacturing process to produce unit dose, liquid filled blisters.

Mystic Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialisation of precision ophthalmic and intranasal delivery technologies for drugs and biologics.